AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and nine months ended September 30, 2006. The net loss for the third quarter of 2006 was $6.8 million, or $0.13 per share, compared with a net loss for the third quarter of 2005 of $1.7 million, or $0.04 per share.

Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI's partner Cook Group Inc.

AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and six months ended June 30, 2006. The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of 2005 of $4.9 million, or $0.11 per share.

By Joe Rojas-Burke, The Oregonian, Portland, Ore. Mar. 14--AVI BioPharma Inc. on Monday announced a licensing and royalty agreement with Cook Group Inc., a large, privately held medical device maker.

Cook to Fund All Clinical Development of Three Products for Cardiovascular Restenosis and Develop Products for Peripheral Vascular Diseases AVI BioPharma, Inc. (Nasdaq: AVII), today announced that it has entered into agreements with Cook Group Inc.